Lilly Pill Cuts Body Weight by 10.5% in Patients With Type 2 Diabetes
By Patrick Wingrove(Reuters) -Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of…
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity – Eli Lilly and Company
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal […]
STAT+: Pharmalittle: We’re reading about an AbbVie deal for a psychedelic, Lilly obesity pill trial results, and more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list […]
Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval – CNBC
Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company Eli Lilly’s weight-loss pill meets target in key diabetes trial Financial Times Lilly’s Weight-Loss Pill Moves Ahead […]
Eli Lilly’s weight-loss pill meets target in key diabetes trial – Financial Times
Eli Lilly’s weight-loss pill meets target in key diabetes trial Financial Times Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company Eli Lilly Ready to Seek […]
Should I Be Using Retinol Head to Toe?
Photo-Illustration: by The Cut; Photos: Getty Images We’ve all heard it a bazillion times: Retinol is the gold-standard anti-aging ingredient. The vitamin-A derivative has been extensively clinically researched and proven to boost collagen production, improving skin’s tone, texture, and firmness. But you have to get through the hard part first: When you begin to use […]
STAT+: Eli Lilly’s obesity pill helped lower weight, blood sugar in key Phase 3 trial
Eli Lilly’s investigational obesity pill helped lower weight and blood sugar in patients with obesity and type 2 diabetes, but the Phase 3 results may not be enough to assuage concerns about the competitiveness of the drug. The medication, called orforglipron, is the most advanced small-molecule GLP-1 in development. Treatment with the drug led to […]
Lilly rounds out oral GLP-1 approval bid with phase 3 obesity win for patients with diabetes
Eli Lilly reported that all three doses of its oral GLP-1 orforglipron helped patients who are obese or overweight with Type 2 diabetes achieve “significant” weight loss in a phase 3 trial. The drug also helped patients reduce their average blood sugar levels and curb cardiometabolic risk factors at 72 weeks.
Lilly plans GLP-1 pill filing after trial success in obesity and diabetes
Eli Lilly’s oral GLP-1 helped patients with both obesity and type 2 diabetes lose up to 9.6% of their weight after about 17 months, new Phase 3 data show. Armed with data from another successful …
A world on weight loss drugs: How GLP-1s are reshaping the economy
As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for both health outcomes and the economy.